Erratum: Evaluation of the Modified Naranjo Criteria for Assessing Causal Attribution of Clinical Outcome to Homeopathic Intervention as Presented in Case Reports

The corresponding author has brought to the publisher's attention that the contribution of HPCUS was inadvertently omitted in the above article published online on March 25, 2020, in Homeopathy (DOI: 10.1055/s-0040-1701251). The corrected article now contains the necessary amendments both in the text and the acknowledgment section as mentioned below.

• Introduction, para 3, sentence 3: The Modified Naranjo Criteria for Homeopathy (Causal Attribution Inventory) tool, originally adapted by Rutten and further developed over several years by the Clinical Data Working Group of the Homoeopathic Pharmacopoeia Convention of the United States (HPCUS), is proposed to assess the likelihood of causal attribution of the clinical outcome to the medicine(s) prescribed in homeopathic cases and case reports. ^8–10

• Introduction, para 4, sentence 1: When homeopathy is tested in clinical trials, understanding and appraisal are likely to be improved if published reports contain details of prescribing strategies and treatment as indicated in the homeopathy-specific extension (RedHot) of the CONSORT guidelines. [11]

• Introduction, para 4, sentence 2: Likewise, a homeopathy extension of the CARE clinical case reporting guideline (HOM-CASE) recommends use of the Modified Naranjo Criteria for Homeopathy, which enables assessment of the likelihood of assigning causal relationship between a homeopathic intervention and a clinical improvement. [10]

• Introduction, para 5: The present study was undertaken to assess the reliability and validity of the currently formulated Modified Naranjo Criteria for Homeopathy, [10] and proposes improved domain by-domain wording based on the findings.

• Discussion, para 14, sentence 2: This, in turn, might be attributed to greater public acceptability and case reporting in that country. The case reports were assessed as per contemporary HOM-CASE CARE guidelines [10] for inclusion in the study.

• Acknowledgments, sentence 1: The authors are grateful to Dr. Joyce Frye, Dr. Todd Hoover, Dr. David Riley and Dr. Peter Smith of the HPCUS Clinical Data Working Group for their contribution to the development of the Modified Naranjo Criteria that were used in this project, as well as to Dr. Raj K. Manchanda, Former Director General and Dr. Anil Khurana, Director General, CCRH for their support.

• References: References 10 and 11 have been transposed as shown below:

Publikationsverlauf

Artikel online veröffentlicht:
21. Oktober 2020

• 10 van Haselen RA. Homeopathic clinical case reports: development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline. Complement Ther Med 2016; 25: 78-85
• 11 Dean ME, Coulter MK, Fisher P, Jobst KA, Walach H. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. J Altern Complement Med 2007; 13: 19-23